Krystal Biotech, Inc. (KRYS) Current Ratio
- Current ratio · latest quarter: Value 8.32×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 8.32× | Current assets / current liabilities. $1.06B ÷ $127.40M ≈ 8.32× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 1.06B USD | Assets, Current |
| Current obligations | 127.40M USD | Liabilities, Current |
| Cash and equivalents | 427.74M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 417.89M USD | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 138.66M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 45.56M USD | Inventory, Net |
| Payables | 6.54M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.06B | $127.40M | $427.74M | $417.89M | $138.66M | $45.56M | $6.54M | (m) | 8.32× |
| 2026-03-31 | $1.02B | $107.80M | $501.31M | $322.09M | $127.02M | $42.65M | $4.09M | (m) | 9.46× |
| 2025-12-31 | $1.02B | $102.94M | $496.30M | $331.49M | $127.42M | $40.48M | $3.24M | (m) | 9.95× |
| 2025-09-30 | $925.65M | $91.27M | $392.60M | $338.46M | $129.63M | $37.63M | $2.10M | (m) | 10.14× |
| 2025-06-30 | $841.35M | $86.90M | $353.83M | $328.16M | $111.44M | $31.04M | $7.12M | (m) | 9.68× |
| 2025-03-31 | $766.80M | $79.49M | $308.77M | $308.08M | $103.26M | $29.94M | $2.67M | (m) | 9.65× |
| 2024-12-31 | $742.04M | $102.00M | $344.87M | $252.65M | $104.75M | $26.51M | $4.99M | (m) | 7.28× |
| 2024-09-30 | $713.16M | $89.53M | $373.97M | $214.36M | $97.30M | $18.58M | $5.58M | (m) | 7.97× |
| 2024-06-30 | $682.77M | $71.85M | $345.79M | $213.83M | $103.24M | $12.18M | $5.42M | (m) | 9.50× |
| 2024-03-31 | $602.25M | $47.59M | $359.01M | $179.25M | $46.47M | $11.04M | $5.36M | (m) | 12.66× |
| 2023-12-31 | $587.91M | $33.09M | $358.33M | $173.85M | $42.04M | $6.99M | $4.13M | (m) | 17.76× |
| 2023-09-30 | $582.13M | $27.58M | $373.24M | $188.83M | $9.32M | $5.28M | $4.34M | (m) | 21.10× |
| 2023-06-30 | $484.00M | $23.90M | $275.88M | $201.64M | (m) | (m) | $4.45M | (m) | 20.25× |
| 2023-03-31 | $355.43M | $35.08M | $140.75M | $209.64M | (m) | (m) | $4.11M | (m) | 10.13× |
| 2022-12-31 | $383.78M | $28.85M | $161.90M | $217.27M | $0.00 | $0.00 | $3.98M | (m) | 13.30× |
| 2022-09-30 | $397.58M | $28.03M | $186.41M | $208.01M | (m) | (m) | $5.76M | (m) | 14.18× |
| 2022-06-30 | $428.77M | $34.43M | $218.72M | $206.84M | (m) | (m) | $9.23M | (m) | 12.45× |
| 2022-03-31 | $438.00M | $60.44M | $269.30M | $165.33M | (m) | (m) | $8.21M | (m) | 7.25× |
| 2021-12-31 | $442.27M | $25.74M | $341.25M | $96.85M | (m) | (m) | $8.40M | (m) | 17.18× |
| 2021-09-30 | $345.81M | $35.78M | $286.61M | $56.48M | (m) | (m) | $4.76M | (m) | 9.67× |
| 2021-06-30 | $369.93M | $18.12M | $329.53M | $38.20M | (m) | (m) | $1.26M | (m) | 20.42× |
| 2021-03-31 | $405.83M | $9.14M | $402.17M | $1.25M | (m) | (m) | $1.84M | (m) | 44.38× |
| 2020-12-31 | $275.06M | $15.45M | $268.27M | $2.99M | (m) | (m) | $2.10M | (m) | 17.80× |
| 2020-09-30 | $287.65M | $7.20M | $282.37M | $4.00M | (m) | (m) | $2.59M | (m) | 39.96× |
| 2020-06-30 | $298.54M | $5.83M | $291.68M | $5.50M | (m) | (m) | $1.61M | (m) | 51.20× |
| 2020-03-31 | $188.33M | $4.06M | $180.22M | $6.48M | (m) | (m) | $636.00K | (m) | 46.38× |
| 2019-12-31 | $195.88M | $3.33M | $187.51M | $6.17M | (m) | (m) | $1.02M | (m) | 58.88× |
| 2019-09-30 | $204.44M | $3.73M | $194.81M | $8.40M | (m) | (m) | $1.25M | (m) | 54.87× |
| 2019-06-30 | $196.20M | $3.94M | $186.59M | $8.88M | (m) | (m) | $896.00K | (m) | 49.80× |
| 2019-03-31 | $107.89M | $3.24M | $98.01M | $8.62M | (m) | (m) | $1.13M | (m) | 33.28× |
| 2018-12-31 | $112.65M | $2.60M | $103.67M | $8.09M | (m) | (m) | $888.00K | (m) | 43.39× |
| 2018-09-30 | $52.82M | $1.92M | $46.67M | $5.63M | (m) | (m) | $378.00K | (m) | 27.57× |
| 2018-06-30 | $45.71M | $759.00K | $41.81M | $3.64M | (m) | (m) | $214.00K | (m) | 60.22× |
| 2018-03-31 | $47.67M | $452.00K | $47.23M | (m) | (m) | (m) | $89.00K | (m) | 105.46× |
| 2017-12-31 | $49.91M | $640.00K | $49.59M | (m) | (m) | (m) | $193.00K | (m) | 77.99× |
| 2017-09-30 | $52.62M | $2.48M | $52.57M | (m) | (m) | (m) | $550.00K | (m) | 21.26× |
| 2016-12-31 | $2.17M | $43.00K | $1.92M | (m) | (m) | (m) | $42.00K | (m) | 50.44× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |